leadf
logo-loader
viewDunelm Group PLC
(
LSE:DNLM
)

Dunelm to beat profit forecasts as winter sale goes well

Dunelm says it is “well-positioned” in the market thanks to its product range and prices

Dunelm

Dunelm PLC (LON:DNLM) shares rose on Wednesday after the stores group said it expects full-year profit before tax to be “slightly” ahead of expectations as its winter sale in the third quarter has started “well”.

Analyst estimates are in the range of £135mln to £137.3mln but the homewares group said it will beat the top end, in its sixth upgrade in a year.

READ: Dunelm comfy on profit expectations as online sales surge

The FTSE 250 furniture, cushions and curtains retailer said it is “well-positioned” in the market, despite uncertain consumer spending outlook, thanks to its product range and prices.

In the 26 weeks to 28 December, like-for-like revenue rose 6% to £568mln, while gross margin inched up 1.2% to 51.5%. Profit before tax jumped 19% to £83.6mln.

Analysts at 'house' broker Peel Hunt said Dunelm continues to grab market share.

“The growth in customer numbers and Dunelm’s digital capabilities means the group is increasing its relevance in the space, as illustrated by the growth in both store sales and online sales,” they said in a note.

By lunchtime trade, Dunelm shares were 5.9% higher at 1,272p.

 -- Updates share price --

 

Quick facts: Dunelm Group PLC

Follow
LSE:DNLM

Price: 1463 GBX

Market Cap: £2.97 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

CBD Science looks to raise £2M in Series A to advance its plant-based...

CBD Science Group PLC CEO Dr Michael Raymont joined Proactive New York to discuss the London, England-based group's Series A funding round, on the Crowd for Angels platform. Raymont says the privately-held company, which is developing plant-based cannabinoid pharmaceutical therapeutics to...

10 hours, 37 minutes ago

2 min read